Pyrazolopyridines and triazolopyridines as A2A / A2B inhibitors
AssigneeIncyte Corporation
InventorsTaisheng Huang, Xiaozhao Wang
Life of this patent
Estimating the term…
Abstract
This application relates to compounds of Formula (I): or pharmaceutically acceptable salts thereof, which modulate the activity of adenosine receptors, such as subtypes A2A and A2B receptors, and are useful in the treatment of diseases related to the activity of adenosine receptors including, for example, cancer, inflammatory diseases, cardiovascular diseases, and neurodegenerative diseases.
Claims12
A method of treating a disease or disorder selected from bladder cancer, lung cancer, breast cancer, ovarian cancer, colorectal cancer, prostate cancer, and head and neck cancer in a patient, comprising administering to said patient a therapeutically effective amount of 3-(4-amino-2-((3-fluoropyridin-2-yl)methyl)-7-(pyrimidin-4-yl)-2H-[1,2,3]triazolo[4,5-c]pyridin-6-yl)benzonitrile, or a pharmaceutically acceptable salt thereof.
Dependencies are inferred from the claim text.